Short answer
Scholar Rock Holding Corp (SRRK) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results released for period ended June 30, 2026.
Scholar Rock Holding Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results released for period ended June 30, 2026
- Financial and operating details furnished in Exhibit 99.1
- Exhibit not deemed filed under Exchange Act Section 18
- Investor analysis requires reviewing the referenced press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $109.9M, or $0.84 per share, broadly stable year over year despite 16% higher weighted-average shares
- Cash, equivalents and marketable securities $492.1M, including $62.8M ATM proceeds, supporting launch preparation and ongoing trials
- Apitegromab FDA decision remains targeted for September 30, 2026, with a second fill-finish facility providing an independent approval path
- Catalent Indiana inspection classification remains pending, creating a key manufacturing-related regulatory risk for the U.S. launch
- Phase 2 FORGE trial initiated in FSHD, targeting approximately 60 patients and expanding apitegromab’s potential beyond SMA
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Scholar Rock Holding Corp 8-K filings
Get the next SRRK 8-K as it lands
Follow SRRK for push alerts, or ask the research agent what this filing means.